What then is the impetus to use drugs other than hydroxyurea in patients with ET and how can one best determine their efficacy? This analysis is problematic in that median survival in ET exceeds 2 decades and might not be inferior to that of an age-and sex-matched control population. 12, 14, 26, 27 Therefore, it is next to impossible to show a survival advantage attached to a "new" drug. It is equally statistically challenging to demonstrate the value of a new drug in the control of disease-related complications because of the low baseline rates seen with conventional therapy. For example, in a recent large retrospective study of 435 patients with ET, the 15-year cumulative risks of thrombosis and clonal evolution into either acute myeloid leukemia (AML) or myelofibrosis with myeloid metaplasia (MMM) were 17%, 2%, and 4%, respectively. 12 Furthermore, the risk of both thrombosis and bleeding in low-risk patients who are not receiving any cytoreductive therapy may not be significantly different from that of the age-and sex-matched control population. 6 On the other hand, the antithrombotic value of cytoreductive therapy for high-or intermediate-risk ET has been addressed by 2 randomized treatment trials, both of which clearly documented the therapeutic superiority of hydroxyurea over both observation alone or anagrelide therapy. 4, 7 In the first study, treatment with hydroxyurea was compared to observation alone in 114 patients, and the risk of thrombosis was significantly less in the treated group (3.6% vs 24% at a median followup of 27 months). 4 Only one minor gastrointestinal bleeding episode occurred in patients treated with hydroxyurea. The results from the second study have recently been communicated at a major international meeting (December 5, 2004 ) and published as an abstract. 7 In the particular study, 809 patients were assigned to treatment with either hydroxyurea or anagrelide, both in combination with aspirin therapy. After a median follow-up of 39 months, the composite risk of both thrombosis and bleeding was once again favorably affected by hydroxyurea treatment (36 vs 55 events in the anagrelide arm).
What about the impact of new drugs on the issue of clonal progression as well as possible drug leukemogenicity associated with hydroxyurea use? In the aforementioned large retrospective study of ET (N=435), 12 the 15-year cumulative risk of either AML (2%) or MMM (4%) was not significantly influenced by single-agent chemotherapy of any kind including hydroxyurea. 12 In addition, the fact that these episodes of clonal evolution occurred at a median of 14.5 and 10.9 years, respectively, again underscores the magnitude of the problem of sample size and duration of follow-up necessary for a controlled study to allow statistically valid conclusions. Two other smaller retrospective studies involving 25 respectively, of treatment with hydroxyurea. Consistent with the observation from these retrospective studies, the risk of leukemic transformation in the aforementioned randomized treatment trials was not adversely affected by the use of hydroxyurea alone, whereas patients treated with anagrelide experienced a significantly higher rate of transformation into MMM (16 vs 5 events on the hydroxyurea arm after a median follow-up of 39 months). 7 Similarly, another recent communiqué, involving 90 patients with ET, suggested a substantial increase in bone marrow fibrosis after treatment with interferon alfa. 30 Therefore, at this juncture, there is no hard evidence to implicate hydroxyurea use in ET as being leukemogenic, whereas new information suggests that both anagrelide and interferon alfa may increase the risk of transformation into MMM. 7, 30 Where do we go from here? Based on the aforementioned discussions, it is reasonable to question the practical impact as well as return value of additional randomized treatment trials in ET. Instead, it might be more costeffective to direct resources and effort toward basic and translational research that focuses on disease pathogenesis and leads to curative therapy. In this regard, the National Institutes of Health recently sent out a request for applications (expiration date, February 17, 2005) for MPD research that focuses on the cellular and genetic characteristics of these disorders (http://grants1.nih.gov/grants/guide /rfa-files/rfa-hl-04-034.html). In the meantime, current evidence continues to support the use of hydroxyurea as the preferred drug of choice for high-risk patients with ET. The remarkably low incidence of AML in hydroxyurea-treated patients with either ET or polycythemia vera, 31 despite the fact that it is usually administered to patients who are vulnerable to clonal evolution because of either aggressive disease phenotype or advanced age, should dispel the unsubstantiated fear of drug leukemogenicity and provides much-needed comfort to physicians who practice evidence-based medicine and use this particular agent for prevention of MPD-associated thrombosis. 4, 28, 32, 33 Finally, the experience in ET should serve as a lesson in discouraging the blanket use of new drugs in polycythemia vera before their value is properly evaluated in a randomized setting.
